20
Participants
Start Date
August 31, 2007
Primary Completion Date
September 30, 2007
Study Completion Date
September 30, 2007
insulin detemir
Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
Novo Nordisk Investigational Site, Beijing
Lead Sponsor
Novo Nordisk A/S
INDUSTRY